Jonathan Anderman
General Counsel at COMPASS THERAPEUTICS, INC.
Jonathan Anderman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| COMPASS THERAPEUTICS, INC. | General Counsel | 31/07/2021 | - |
| Corporate Secretary | 31/07/2021 | - |
Career history of Jonathan Anderman
Former positions of Jonathan Anderman
| Companies | Position | Start | End |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 31/12/2019 | 31/07/2021 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 31/07/2015 | 31/07/2018 |
Training of Jonathan Anderman
| Boston University School of Law | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 2 |
| General Counsel | 1 |
| Corporate Secretary | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| COMPASS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jonathan Anderman
- Experience
